Literature DB >> 10704958

Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo.

A L Sharpley1, C M Vassallo, P J Cowen.   

Abstract

BACKGROUND: The study aimed to determine the effects of the atypical antipsychotic agent, olanzapine, on the polysomnogram in healthy subjects. We predicted that olanzapine, via serotonin(2C) (5-HT(2C)) receptor blockade, would increase slow-wave sleep (SWS).
METHODS: We studied the effects of single evening doses of olanzapine (5 mg and 10 mg orally) on the polysomnogram of 9 healthy male volunteers, using a placebo-controlled, double-blind, cross-over design.
RESULTS: Compared to placebo, the 5-mg and 10-mg doses of olanzapine significantly increased SWS, sleep continuity measures, and subjective sleep quality. In addition, 10 mg of olanzapine suppressed rapid eye movement (REM) sleep and increased REM sleep latency.
CONCLUSIONS: Olanzapine (5 mg and 10 mg) produced substantial (59.1% and 83.3%) and highly significant dose-related increases in SWS in humans probably via blockade of brain 5-HT(2C) receptors. 5-HT(2C) receptor antagonism may account for some of the therapeutic and adverse effects of olanzapine therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704958     DOI: 10.1016/s0006-3223(99)00273-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  27 in total

Review 1.  Drug-induced sleep: theoretical and practical considerations.

Authors:  Jeffrey M Ellenbogen; Edward F Pace-Schott
Journal:  Pflugers Arch       Date:  2011-09-28       Impact factor: 3.657

2.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

3.  Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.

Authors:  Sandra Giménez; Susana Clos; Sergio Romero; Eva Grasa; Adelaida Morte; Manuel J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

4.  Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms.

Authors:  S Devarajan; J Ali; S M Dursun
Journal:  Psychopharmacology (Berl)       Date:  2006-03-15       Impact factor: 4.530

Review 5.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

6.  Olanzapine causes a leptin-dependent increase in acetylcholine release in mouse prefrontal cortex.

Authors:  Asheley B Wathen; Emily S West; Ralph Lydic; Helen A Baghdoyan
Journal:  Sleep       Date:  2012-03-01       Impact factor: 5.849

Review 7.  Sleep-dependent memory consolidation and its implications for psychiatry.

Authors:  Monique Goerke; Notger G Müller; Stefan Cohrs
Journal:  J Neural Transm (Vienna)       Date:  2015-10-30       Impact factor: 3.575

Review 8.  The role of antipsychotics in the management of fibromyalgia.

Authors:  Elena P Calandre; Fernando Rico-Villademoros
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

Review 9.  Role of atypical antipsychotics in the treatment of generalized anxiety disorder.

Authors:  Rachel Hershenberg; Daniel F Gros; Olga Brawman-Mintzer
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

Review 10.  Psychiatric disorders and sleep.

Authors:  Andrew D Krystal
Journal:  Neurol Clin       Date:  2012-11       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.